Enrichment of chitosan hydrogels with perfluorodecalin promotes gelation and stem cell vitality

Thermosensitive injectable hydrogels for bone regeneration consisting of chitosan, sodium beta-glycerophosphate (Na-β-GP) and alkaline phosphatase (ALP) were enriched with oxygenated perfluorodecalin (PFD), a liquid hydrophobic perfluorochemical with high oxygen affinity, in order to improve cell growth on the hydrogels. Furthermore, influence of PFD concentration on hydrogel physicochemical properties relevant for bone regeneration, namely gelation speed, radiopacity and homogenicity, was investigated. Addtionally, ALP-mediated and non-ALP-mediated mineralization were evaluated by incubation in 0.1 M calcium glycerophosphate and simulated body fluid. 2% (w/v) chitosan hydrogels containing 2.5 mg/ml ALP were enriched with PFD at five concentrations, namely 0 (control), 0.069, 0.138, 0.207 and 0.276 ml/ml hydrogel, denoted A, B, C, D and E, respectively. Rheometrical investigations revealed that gelation speed increased with increasing PFD concentration. Micro-CT analysis revealed homogenicity of all sample groups except E and that radiopacity increased in the order B>C>A>D>E. ALP-mediated and non-ALP-mediated mineralization were not affected adversely by PFD. Growth of human adipose tissue-derived mesenchymal stem cells (ADSC) encapsulated in hydrogels was markedly higher in sample groups containing PFD, i.e. B–E. Hence, incorporation of oxygenated PFD can improve the suitability of hydrogels as bone regeneration materials

Allogenic Adipose-Derived Stem Cells in Diabetic Foot Ulcer Treatment: Clinical Effectiveness, Safety, Survival in the Wound Site, and Proteomic Impact

Although encouraging results of adipose-derived stem cell (ADSC) use in wound healing are available, the mechanism of action has been studied mainly in vitro and in animals. This work aimed to examine the safety and efficacy of allogenic ADSCs in human diabetic foot ulcer treatment, in combination with the analyses of the wound. Equal groups of 23 participants each received fibrin gel with ADSCs or fibrin gel alone. The clinical effects were assessed at four time points: days 7, 14, 21 and 49. Material collected during debridement from a subset of each group was analyzed for the presence of ADSC donor DNA and proteomic changes. The reduction in wound size was greater at all subsequent visits, significantly on day 21 and 49, and the time to 50% reduction in the wound size was significantly shorter in patients who received ADSCs. Complete healing was achieved at the end of the study in seven patients treated with ADSCs vs. one treated without ADSCs. One week after ADSC application, 34 proteins significantly differentiated the material from both groups, seven of which, i.e., GAPDH, CAT, ACTN1, KRT1, KRT9, SCL4A1, and TPI, positively correlated with the healing rate. We detected ADSC donor DNA up to 21 days after administration. We confirmed ADSC-related improvement in wound healing that correlated with the molecular background, which provides insights into the role of ADSCs in wound healing—a step toward the development of cell-based therapies